Xenon Pharmaceuticals Inc (US: XENE) — Healthcare · Share Price, Chart & Market Data
About: Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $55.24 (-0.31%)
XENEXenon Pharmaceuticals Inc
Loading watchlist status…
Trade XENE now
Xenon Pharmaceuticals Inc share price
XENE price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 1:36 pm GMT+0
XENE price performance
-2.057%
5D
1.395%
1M
24.163%
YTD
45.983%
1Y
XENE price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 1:36 pm GMT+0
XENE details
XENE Market Signals